Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BOLD

Audentes Therapeutics (BOLD) Stock Price, News & Analysis

Audentes Therapeutics logo

About Audentes Therapeutics Stock (NASDAQ:BOLD)

Advanced Chart

Key Stats

Today's Range
$2.36
$2.58
50-Day Range
$59.97
$59.97
52-Week Range
$1.06
$12.26
Volume
96,520 shs
Average Volume
85,379 shs
Market Capitalization
$35.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Receive BOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLD Stock News Headlines

Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Guggenheim Downgrades Boundless Bio (BOLD)
Boundless Bio Announces Pipeline and Leadership Updates
See More Headlines

BOLD Stock Analysis - Frequently Asked Questions

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, March, 27th. The biotechnology company reported ($0.74) EPS for the quarter, hitting the consensus estimate of ($0.74).

Audentes Therapeutics (BOLD) raised $100 million in an initial public offering on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

Last Earnings
3/27/2025
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BOLD
Fax
N/A
Employees
207
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-49,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
21,118,000
Market Cap
$35.68 million
Optionable
No Data
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:BOLD) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners